Core Insights - Medpace reported another strong quarter with significant sales and profit growth, leading to a guidance hike for the full year [2][7][9] Financial Performance - Medpace achieved adjusted earnings of $3.86 per share, exceeding expectations of $3.37, marking a growth of over 28% [7] - Revenue increased nearly 24% to $659.9 million, surpassing forecasts of $641 million, representing the third consecutive quarter of accelerating sales growth [7] - The company secured $789.6 million in new business awards, a 48% increase, resulting in a book-to-bill ratio of 1.2x, outperforming analyst expectations of 1.1x to 1.13x [3][4] Guidance and Outlook - Medpace raised its full-year earnings guidance to a range of $14.60 to $14.86 per share, an increase of approximately 59 cents at the midpoint from previous guidance [9] - The sales forecast was also adjusted to $2.48 billion to $2.53 billion, up from the previous range of $2.42 billion to $2.52 billion [9] Analyst Commentary - Analysts described the quarter as "flawless," with strong pull-through on revenue and new bookings exceeding expectations [2][3] - The significant increase in bookings over the last couple of quarters surprised analysts, indicating a positive trend in the biotech funding environment [5][6]

Q3 2025 FINANCIAL RESULTS OCTOBER 22, 2025 FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward- looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate ...

Group 1: Market Overview - Wall Street's three main equity benchmarks closed lower, with Netflix dropping over -10% after reporting weaker-than-expected Q3 EPS, and Texas Instruments sliding more than -5% due to underwhelming Q4 guidance [2] - Higher bond yields are impacting stock index futures, with Treasury yields climbing as oil prices surged over +5% following U.S. sanctions on Russian oil companies [3][10] - The Euro Stoxx 50 Index rose +0.18% as investors reacted positively to corporate earnings reports, particularly in the energy sector due to rising oil prices [10] Group 2: Corporate Earnings - Companies in the S&P 500 are expected to post an average +7.2% increase in Q3 earnings compared to the previous year, marking the smallest rise in two years [6] - Tesla reported weaker-than-expected Q3 adjusted EPS despite a sales surge, leading to a pre-market drop of over -3% [4][14] - Medpace Holdings surged over +18% in pre-market trading after posting upbeat Q3 results and raising its full-year guidance [4][15] Group 3: Economic Indicators - The U.S. government shutdown has delayed the publication of weekly jobless claims, with investors focusing on existing home sales data expected to show 4.06 million in September [7] - Fed rate futures indicate a 96.7% probability of a 25 basis point rate cut at the upcoming monetary policy meeting [8] - France's manufacturing business climate index climbed to a 1-1/2-year high in October, surpassing its long-term average for the first time since early March 2024 [10][11] Group 4: International Developments - China's Shanghai Composite Index closed higher on hopes for fresh stimulus measures and de-escalation in U.S.-China trade tensions, with financial stocks leading gains [12] - Japan's Nikkei 225 Index closed lower as investors took profits following a recent rally, with technology stocks leading the declines [13]

Market Overview - U.S. stock futures experienced volatility following declines on Wednesday, with major benchmark indices showing lower futures [1] - Disappointing earnings guidance and escalating U.S.-China trade tensions have negatively impacted investor confidence [1] - The Trump administration is contemplating new export restrictions to China, targeting products made with U.S.-developed software [1] Treasury Yields and Federal Reserve Outlook - The 10-year Treasury bond yielded 3.98%, while the two-year bond was at 3.46% [2] - Market projections indicate a 96.7% likelihood of the Federal Reserve cutting interest rates in its October meeting [2] Stock Performance Highlights - Tesla Inc. (NASDAQ:TSLA) fell 3.04% in premarket trading despite reporting better-than-expected revenue for Q3, with earnings missing estimates [6] - International Business Machines Corp. (NYSE:IBM) dropped 7.14% despite better-than-expected financial results, but raised its full-year 2025 revenue growth guidance to "more than" 5% [6] - American Airlines Group Inc. (NASDAQ:AAL) rose 1.41% as analysts anticipate a quarterly loss of 28 cents per share on revenue of $13.63 billion [6] - Medpace Holdings Inc. (NASDAQ:MEDP) surged 18.52% after reporting Q3 revenue of $659.9 million and earnings of $3.86 per share, both exceeding analyst estimates [12] Economic Data and Analyst Insights - Initial jobless claims data will be delayed due to an impending shutdown, with existing home sales for September expected to be released at 10:00 a.m. ET [13] - Mike Wilson, Morgan Stanley's CIO, argues that the Federal Reserve is "behind the curve" and should implement significant rate cuts to align with market conditions [9][10] Commodities and Global Markets - Crude oil futures increased by 5.220% to approximately $61.54 per barrel [14] - Gold Spot prices rose 0.38% to around $4,114.22 per ounce, while Bitcoin traded 1.16% higher at $109,323.15 per coin [14]

Market Overview - U.S. stock futures experienced volatility following declines on Wednesday, with major benchmark indices showing lower futures [1] - Disappointing earnings guidance and escalating U.S.-China trade tensions have negatively impacted investor confidence [1] - The Trump administration is contemplating new export restrictions to China, targeting products made with U.S.-developed software [1] Economic Indicators - The 10-year Treasury bond yielded 3.98%, while the two-year bond was at 3.46% [2] - Market expectations indicate a 96.7% likelihood of the Federal Reserve cutting interest rates in its October meeting [2] Stock Performance - Tesla Inc. (NASDAQ:TSLA) fell 3.04% in premarket trading despite reporting better-than-expected revenue for Q3, with earnings missing estimates [6] - International Business Machines Corp. (NYSE:IBM) dropped 7.14% despite better-than-expected Q3 results, but raised its full-year 2025 revenue growth guidance to "more than" 5% [6] - American Airlines Group Inc. (NASDAQ:AAL) rose 1.41% as analysts anticipate a quarterly loss of 28 cents per share on revenue of $13.63 billion [6] - Medpace Holdings Inc. (NASDAQ:MEDP) surged 18.52% after reporting Q3 revenue of $659.9 million and earnings of $3.86 per share, both exceeding analyst estimates [12] - Ford Motor Co. (NYSE:F) shares remained unchanged ahead of its earnings report, with analysts expecting earnings of 36 cents per share on revenue of $43.08 billion [12] Sector Performance - Most sectors on the S&P 500 closed negatively, with communication services, industrials, and consumer discretionary stocks experiencing the largest losses [7] Analyst Insights - Mike Wilson, Morgan Stanley's CIO, argues that the Federal Reserve is "behind the curve" and needs to implement "meaningful" rate cuts, suggesting a need for cuts of 150 basis points or more [9][10] - Wilson believes the economy has transitioned into an "early cycle new recovery," dismissing recent market volatility as part of a new economic cycle [11]

Core Insights - Biotech stocks experienced significant gains in after-hours trading on October 22, 2023, primarily driven by Ventyx Biosciences' positive Phase 2 data, which led to an 88% surge in its stock price [1][2]. Company Performance - Ventyx Biosciences Inc. (VTYX) saw its shares increase by over 88% following the announcement of positive results from its Phase 2 study of VTX3232 for patients with obesity and cardiovascular risk factors [2]. - Medpace Holdings, Inc. (MEDP) reported better-than-expected Q3 results, resulting in an over 18% increase in its stock price during after-hours trading [2]. - Inhibrx Biosciences Inc. (INBX) shares rose over 10% to $34.98 after announcing a live webcast presentation to discuss topline results from the ChonDRAgon study [3]. - SCYNEXIS Inc. (SCYX) shares increased by over 11% to $0.87 [4]. - Acumen Pharmaceuticals Inc. (ABOS) experienced a notable rise of over 24.9% to $2.31 [4]. - Rani Therapeutics Holdings Inc. (RANI) shares were up over 9% at $2.64 [4]. - iBio Inc. (IBIO) shares increased by over 7% to $1.50 [4]. - Chemomab Therapeutics Ltd. (CMMB) shares rose over 7% to $3.32 [4]. - Nautilus Biotechnology Inc. (NAUT) shares increased by over 7% to $1.35 [4]. - ProQR Therapeutics N.V. (PRQR) shares were up over 7% at $2.92 [4]. - Tyra Biosciences Inc. (TYRA) shares increased by over 7% to $15.00 [4]. - Imunon Inc. (IMNN) shares rose over 4% to $4.90 [4].

Core Insights - The Optimist Fund achieved a return of +9.1% in Q3 2025, significantly outperforming its benchmark [5] - The fund's year-to-date return stands at 44.5%, compared to the benchmark's 11.1% [5] - The fund anticipates continued growth opportunities over the next three and a half years, similar to recent performance [4] Fund Performance - The fund's performance over various periods shows significant volatility, with a notable recovery from a -51.4% return in 2022 to 82.9% in 2023 [5] - Compound returns as of September 30, 2025, indicate strong performance across 1-year (61.2%), 2-year (65.6%), and 3-year (61.9%) periods [5] Top Contributors - **Wayfair**: Revenue increased by approximately 5% year-over-year to $3.27 billion, marking its fastest growth since Q1 2021. Adjusted EBITDA reached $205 million, indicating a margin above 6% for the first time since Q2 2021 [7][8][9] - **ThredUp**: Revenue rose 16% year-over-year to $77.7 million, with adjusted EBITDA increasing by around 100%. Active buyers grew by 17% to 1.47 million [10][11][12] - **Carvana**: Retail units sold increased by 41% year-over-year to 143,280 vehicles, with total revenue rising 42% to $4.84 billion. Adjusted EBITDA reached $601 million, reflecting a 12.4% margin [13][14][15] Top Detractors - **Monday.com**: Despite a 27% increase in revenue, the company reduced its second-half 2025 revenue guidance due to weaker performance marketing trends, causing investor concerns [20][21][22] - **Fiverr**: Results were below expectations, leading to a reduction in position size despite maintaining an attractive risk/reward profile [25][26] Portfolio Composition - The top 10 holdings comprise approximately 85% of the portfolio, including ThredUp, Monday.com, Carvana, Uber, Wayfair, DoorDash, First Advantage, Fiverr, Latham Group, and Medpace [27] Notable Changes - The fund exited positions in HelloFresh and Revolve due to management changes and reduced confidence in growth prospects, reallocating capital to more promising opportunities [29][30] Company Insights - **Medpace**: A leading contract research organization (CRO) focused on small and mid-sized biotech companies, showing strong revenue growth of 14.2% year-over-year to $603.3 million [31][18][35] - The company has a disciplined capital allocation strategy, with a history of share repurchases during market downturns, enhancing long-term growth potential [34][35]

Medpace (MEDP) came out with quarterly earnings of $3.86 per share, beating the Zacks Consensus Estimate of $3.5 per share. This compares to earnings of $3.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.29%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $3 per share when it actually produced earnings of $3.1, delivering a surprise of +3.33%.Over the ...

Exhibit 99.1 Investor Contact: Lauren Morris 283-227-6409 l.morris@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 283-227-6367 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2025 Results CINCINNATI, OHIO, October 22, 2025-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue for the three months ended September 30, 2025 increased 23.7% to $659.9 milli ...

Core Insights - Medpace Holdings, Inc. reported a revenue increase of 23.7% for Q3 2025, reaching $659.9 million compared to $533.3 million in Q3 2024 [1] - On a constant currency basis, revenue growth for Q3 2025 was 23.4% compared to the same period in the previous year [1] - The company's backlog as of September 30, 2025, indicates strong future revenue potential [1]